News
Find all the latest news from Frontier Science Scotland below
choose a category:
Cardiac Safety in the APHINITY trial
ESMO Open has published an article confirming the cardiac safety of adjuvant anti-HER2 treatment with pertuzumab and trastuzumab.
An Interview with FSS Executive Director, Darren Gibson
Discover more about Darren, what he’s been focused on during the first 12 months in his new role and his plans for Frontier Science Scotland
NeoALTTO: European Journal of Cancer (EJC)
Ten-year survival of neoadjuvant dual HER2 blockade in patients with HER2-positive breast cancer
Overall survival in the OlympiA trial
OlympiA demonstrates statistically significant improvement in overall survival with adjuvant olaparib compared with placebo
EPoS
The EPoS (European Polyp Surveillance) study is a group of related randomised controlled clinical trials which aim to address the optimum colonoscopy surveillance interval for patients who have had premalignant polyps identified and removed from the large bowel, in...
NordICC
Learn how Frontier science scotland partnered with the University of Oslo for the nordicc study In collaboration with the University of Oslo, FSS held responsibility for trial data collection, management and cleaning processes. After inheriting the original Case...
FINESSE
Frontier Science has worked in partnership with the Breast International Group (BIG), Breast European Adjuvant Study Team (BrEAST) and in collaboration with Institut de Recherches Internationales SERVIER on the FINESSE trial. The trial was an open, 3-cohort, phase II...
ALEXANDRA
ALEXANDRA is a clinical trial partnership between Roche, the Breast International Group (BIG), Alliance Foundation Trials (AFT), Institut Jules Bordet (IJB) and Frontier Science. This is a phase 3, multicentre, randomised, open-label study comparing atezolizumab...
TOMORROW
Frontier Science collaborated with Janssen Actelion on the TOMORROW trial. The study assessed the efficacy, safety and pharmacokinetics of macitentan (Opsumit®) versus standard of care in children with pulmonary arterial hypertension (PAH). Frontier Science (Scotland)...
ALTTO & NEO-ALTTO
Frontier Science collaborated with the Breast International Group (BIG) on the ALTTO and Neo-ALTTO trials. These trials were built on the results from the successful HERA trial and aimed to study the benefit of adding Lapatinib to Herceptin® in both adjuvant and...
APHINITY
APHINITY is a large, randomised phase III, double-blind, placebo-controlled study that compares the efficacy and safety of chemotherapy plus trastuzumab and placebo with that of chemotherapy plus trastuzumab and pertuzumab as adjuvant therapy in approximately 4800...
OlympiA
OlympiA is a randomized, double-blind, parallel group, placebo-controlled multi-center phase III study to assess the efficacy and safety of olaparib versus placebo as adjuvant treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary...
NoTOPain
NoTOPain was a randomised, crossover, placebo controlled, double-blind, Phase II study of cetuximab in patients with treatment-refractory, non-malignant severe chronic neuropathic pain. Neuropathic pain is a subtype of pain that can be caused by a variety of...
APHINITY | Annals of Oncology
Adjuvant pertuzumab and trastuzumab in patients with early HER-2 positive breast cancer in APHINITY: 8.4 years’ follow-up
OlympiA | ESMO Virtual Plenary Abstract | Annals of Oncology
Pre-specified event driven analysis of Overall Survival (OS) in the OlympiA phase III trial of adjuvant olaparib (OL) in germline BRCA1/2 mutation (gBRCAm) associated breast cancer
APHINITY | Journal of the National Cancer Institute (JNCI)
Impact of age on clinical outcomes and efficacy of adjuvant dual anti-HER2 targeted therapy
APHINITY | European Journal of Cancer (EJC)
Six-year absolute invasive disease-free survival benefit of adding adjuvant pertuzumab to trastuzumab and chemotherapy for patients with early HER2-positive breast cancer: A Subpopulation Treatment Effect Pattern Plot (STEPP) analysis of the APHINITY (BIG 4-11) trial
APHINITY | AACR Cancer Research
Effect of young age at diagnosis on clinical outcomes and efficacy of anti-HER2 targeted therapy in patients with HER2-positive early breast cancer: Results from the APHINITY trial.
The ALTTO Trial: Updated Results from the international phase III ALTTO trial (BIG2-06/Alliance N063D)
Presentation of the pre-specified analyses of >5-years follow-up of the Phase III ALTTO trial as shown at the 2017 annual meeting of the American Society of Clinical Oncology and published in the European Journal of Cancer in 2021.
The APHINITY Trial: Results of the Interim Overall Survival Analysis at 6 years’ follow-up
The JCO confirms the invasive disease-free survival benefit from adding pertuzumab to standard adjuvant therapy for patients with node-positive HER2-positive early breast cancer.